The US FDA granted full approval to the antiviral drug Remdesivir as a treatment for patients hospitalized with Covid-19. As an antiviral drug, Veklury #remdesvir works to stop replication of SARS-CoV-2, the virus that causes COVID-19.
The drug is now widely available in hospitals across the United States, following early investments to rapidly expand manufacturing capacity to increase supply.
In the United States, Veklury is indicated for adults and pediatric patients (12 years of age and older and weighing at least 40 kg) for the treatment of COVID-19 requiring hospitalization. Veklury will only be administered in a hospital or in a healthcare setting capable of providing acute care comparable to inpatient hospital care.
“The approval of Veklury marks an important milestone in efforts to help address the pandemic by offering an effective treatment that helps patients recover faster and, in turn, helps preserve scarce healthcare resources,” said Barry Zingman, MD, Professor of Medicine at the Albert Einstein College of Medicine and Montefiore Medical Center, New York.